In its latest Form 13F filing for the third quarter, Burney Co. reported a 1.9% reduction in its position in Eli Lilly, disposing of 546 shares and ending the period with 28,069 shares. At the time of the filing, those shares represented a holding valued at approximately $21.42 million. This modest trimming signals a slight rebalancing by an institutional investor that still maintains a multi-million dollar exposure to Eli Lilly’s growth story.

Several additional funds adjusted their Eli Lilly holdings in the same quarter. Ellsworth Advisors LLC expanded its stake by 66.6%, acquiring 1,719 shares to reach 4,301 shares valued at roughly $3.56 million. Covea Finance reduced its position by 9.9%, selling 4,400 shares and retaining 40,070 shares worth about $30.57 million. Blue Trust Inc. also sold down, offloading 484 shares for a 0.5% reduction, leaving 89,627 shares valued near $68.39 million. These shifts reflect active portfolio management around a stock owned by over 82% institutional investors.

Eli Lilly has drawn a spectrum of research views in recent months. BMO Capital Markets assigned a $1,200 target earlier in December. JPMorgan Chase raised its objective from $1,050 to $1,150 and maintained an overweight rating in mid-November. Loop Capital set a $950 target in early November, while Truist Financial boosted its target from $1,038 to $1,182 alongside a buy recommendation. Conversely, Bank of America trimmed its target marginally from $1,286 to $1,268 but kept a buy rating. Among 26 analysts covering the stock, four rate it Strong Buy, 17 Buy and five Hold, producing a consensus Moderate Buy and an average target near $1,155.

In its October 30th quarterly release, Eli Lilly reported earnings of $7.02 per share on revenue of $17.60 billion, surpassing consensus by $0.60 in EPS and $1.51 billion in sales. The company achieved a net margin close to 31% and posted a return on equity above 109%. Year-over-year quarterly revenue climbed 53.9%, driven largely by strong demand for key growth drugs. Management reiterated full-year EPS guidance of 23.00–23.70 and analysts forecast 23.48 EPS for FY 2025. Eli Lilly’s board also approved a quarterly dividend of $1.73 per share—a 15% increase year-over-year—reflecting a payout ratio below 30% and marking 11 consecutive years of dividend growth.